These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12452247)

  • 1. Sibutramine lost and found.
    Bosello O; Carruba MO; Ferrannini E; Rotella CM
    Eat Weight Disord; 2002 Sep; 7(3):161-7. PubMed ID: 12452247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sibutramine and the management of obesity.
    Poston WS; Foreyt JP
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG; Goulder MA;
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study.
    Milano W; Petrella C; Casella A; Capasso A; Carrino S; Milano L
    Adv Ther; 2005; 22(1):25-31. PubMed ID: 15943219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
    Apfelbaum M; Vague P; Ziegler O; Hanotin C; Thomas F; Leutenegger E
    Am J Med; 1999 Feb; 106(2):179-84. PubMed ID: 10230747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
    Luque CA; Rey JA
    Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
    Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of weight reduction by sibutramine on female sexual function.
    Kim KK; Kang HC; Kim SS; Youn BB
    Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine: current status as an anti-obesity drug and its future perspectives.
    Sharma B; Henderson DC
    Expert Opin Pharmacother; 2008 Aug; 9(12):2161-73. PubMed ID: 18671470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.